• Clinical Trials - Ovarian Cancer

    Study Objective Contact
    A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Niraparib in Women with Advanced, Relapsed, High Grade Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer who have Received at Least Three Previous Chemotherapy Regimens [LCID Study Number: 2015-022] To evaluate the safety and efficacy of investigational medication, niraparib, in patients with ovarian cancer, fallopian tube cancer or peritoneal cancer who have received at least three previous chemotherapy regimens. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Joyce E. Pelletier.
    A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib versus Placebo in Patients with Platinum Sensitive Ovarian Cancer [LCID Study Number: 2014-024] NOVA is a maintenance trial for women with ovarian cancer, aged 18 and older, to find out if niraparib (a PARP inhibitor) can help delay worsening of ovarian cancer among patients who had a good response to previous treatment with a platinum-type chemotherapy drug (i.e. cisplatin, carboplatin). Niraparib will be compared to placebo and patients will be randomized so that 2 out of 3 patients will take niraparib and 1 out of 3 will take placebo. This study is designed with the hope of preventing worsening of the cancer after another treatment has caused the cancer to improve. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Joyce E. Pelletier.
    A Pilot Study: Acupuncture Integrative Care for Ovarian Cancer Patients [LCID Study Number: 2012-046] A Pilot study of Acupuncture Integrative Care for Ovarian Cancer Patients: This study is to learn about the potential benefits of acupuncture treatment for ovarian cancer patients. Principal Investigator(s):
    Jonathan B. Ammen

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Amanda M. Pietras.
    GOG 0186J: A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC#673089) Plus Pazopanib (NSC# 737754) (IND# 75648) versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma [LCID Study Number: 2012-020] The purpose of this study is to compare the effectiveness of the combination of the drugs paclitaxel and pazopanib to the combination of paclitaxel and placebo (sugar pill) in treating ovarian, peritoneal and fallopian tube cancer and to determine the types and severity of side effects caused by treatment with these drug combinations. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Joyce E. Pelletier.
    GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? [LCID Study Number: 2015-037] The purpose of this study is to find out if a change in diet and exercise in women who have completed treatment for stage II, III, or IV ovarian, fallopian tube or primary peritoneal cancer has an effect on the length of cancer free time following initial treatment. Some studies suggest diet and exercise may improve survival for cancer patients, but no studies have been done to show if changes in diet and exercise can have an effect on cancer returning. Other goals include finding out if the changes in diet and exercise will improve overall quality of life and ability to be physically active. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Joyce E. Pelletier.
    GOG 0273: Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer [LCID Study Number: 2012-028] The major goal of this study is to see if physicians can predict how women will tolerate and complete chemotherapy as prescribed using simple assessments looking at your ability to do activities of daily living. Another goal of the study is to look at how chemotherapy works in older women with cancer. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Joyce E. Pelletier.
    GOG-0252: A Phase III Clinical Trial Of Bevacizumab With IV Versus IP Chemotherapy In Ovarian, Fallopian Tube And Primary Peritoneal Carcinoma NCI-Supplied Agent(S): Bevacizumab (NSC #704865, IND #7921) [LCID Study Number: 2010-017] This study will compare IV chemotherapy with two different IP treatment plans (regimens) to determine if there is a survival benefit. This study will also collect information on side effects and possible complications of IP administration, using questionnaires. This study will ask patients how they feel during treatment to assess the risks and benefits of each treatment from the patient’s perspective. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Joyce E. Pelletier,
    Sharon D. Digregorio, RN.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.
    Validation of Biomarkers For Detection of Ovarian Cancer [LCID Study Number: 2010-074] Validation of Biomarkers for Detection of Ovarian Cancer: In collaboration with Tufts Medical Center, this study is to generate and then validate a marker panel that can be used to screen for invasive ovarian malignancy. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Kori D. Hesse.